Report Overview

The EU Leukemia drugs market size stood at USD 2.9 billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period

The leukemia therapeutics market is mainly driven by the rising burden of leukemia cases, high unmet medical need for cancer therapy, and rising investment in healthcare sectors. Among them, the number of new cases of acute myeloid leukemia (AML) was around 21,450. Acute Myeloid Leukemia is thus considered as one of the most common types of leukemia in adults. Hence the overall statistics show that there is a huge number of people that are prone to suffer from leukemia, and which may directly impact the growth of the market in the forecast period



Market Growth Drivers

There has been a tremendous increase in cell-based research activities over the past decade. Increasing research in the field of regenerative medicine for the treatment of leukemia and growing awareness of personalized medicine have also resulted in the growth of this market. In addition to it, the growth in this market is driven by the high prevalence and incidence of leukemia and the rising geriatric population